Fulgent Genetics, Inc. (FLGT) — Stock Score Summary

Fulgent Genetics, Inc. (FLGT) has a MoatMap StockRank of 29/100 based on Quality (41/100), Value (49/100), and Momentum (27/100) factor scores. The current signal is SELL. Fulgent Genetics is sitting on a large post-COVID cash pile, but its core diagnostics business lacks a clear, high-ROIC reinvestment runway or strong thematic tailwinds.

Fulgent Genetics, Inc. is a technology company providing comprehensive genetic testing and genomic data solutions across inherited diseases, cancer, and infectious diseases. The company's competitive moat is its proprietary, high-throughput next-generation sequencing (NGS) platform and advanced bioinformatics, enabling rapid, cost-effective, and highly accurate diagnostic testing. Fulgent leverages its scalable technology to offer an extensive test menu and cater to a broad clinical and research market.

Key Financial Metrics

Price$18.68
Market Cap$518M
P/E (Forward)-12.76
Price/Book0.54
Return on Equity-6.9%
Return on Invested Capital-6.2%
Debt/Equity0.97
Gross Margin38.7%
Operating Margin-45.0%
Revenue Growth-3.2%
Free Cash Flow$-106M

Fulgent Genetics, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Fulgent Genetics, Inc.’s (FLGT) StockRank?
MoatMap’s StockRank for Fulgent Genetics, Inc. (FLGT) is 29/100, with a Sell signal. It is a composite of Quality (41), Value (49), and Momentum (27) factor ranks across MoatMap’s 19,000+ stock universe.
Does Fulgent Genetics, Inc. have an economic moat?
Fulgent Genetics, Inc. (FLGT) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Fulgent Genetics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Fulgent Genetics, Inc. (FLGT) is Sell, based on a StockRank of 29/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Fulgent Genetics, Inc. in?
Fulgent Genetics, Inc. (FLGT) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).
Browse all ranked stocksFLGT deep dive reportAI ChampionsHow we score stocksSense-check another stock